Wockhardt Limited (WOCKPHARMA.BO)
INR 1264.45
(4.26%)
INR 1264.45
(4.26%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.08 Billion INR | -26.42% |
| 2022 | -710 Million INR | -29.57% |
| 2021 | 1.35 Billion INR | 377.78% |
| 2020 | -790 Million INR | -53.91% |
| 2019 | 1.57 Billion INR | 743.85% |
| 2018 | -201.7 Million INR | -157.89% |
| 2017 | -2.41 Billion INR | -53.98% |
| 2016 | 1.24 Billion INR | -85.51% |
| 2015 | 5.6 Billion INR | -26.3% |
| 2014 | 7.75 Billion INR | -29.84% |
| 2013 | 11.13 Billion INR | -49.06% |
| 2012 | 20.88 Billion INR | 51.15% |
| 2011 | 9.13 Billion INR | 48.23% |
| 2010 | 9.31 Billion INR | 9.17% |
| 2009 | 8.53 Billion INR | 1.9% |
| 2008 | 8.37 Billion INR | 21.33% |
| 2007 | 6.9 Billion INR | 64.18% |
| 2006 | 4.2 Billion INR | 15.82% |
| 2005 | 3.61 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 920 Million INR | 346.94% |
| 2023 Q4 | 200 Million INR | -55.56% |
| 2023 FY | - INR | -26.42% |
| 2023 Q1 | 300 Million INR | 25.0% |
| 2023 Q2 | 960 Million INR | 220.0% |
| 2023 Q3 | 450 Million INR | -53.13% |
| 2022 FY | - INR | -29.57% |
| 2022 Q1 | 410 Million INR | 118.72% |
| 2022 Q2 | 1 Billion INR | 143.9% |
| 2022 Q3 | 470 Million INR | -53.0% |
| 2022 Q4 | 240 Million INR | -48.94% |
| 2021 Q3 | 1.13 Billion INR | 11.88% |
| 2021 FY | - INR | 377.78% |
| 2021 Q1 | 1.22 Billion INR | 182.36% |
| 2021 Q2 | 1.01 Billion INR | -17.21% |
| 2021 Q4 | -2.18 Billion INR | -293.78% |
| 2020 Q4 | -1.48 Billion INR | -193.21% |
| 2020 FY | - INR | -53.91% |
| 2020 Q3 | 1.58 Billion INR | 382.45% |
| 2020 Q2 | 329.4 Million INR | 151.39% |
| 2020 Q1 | -641 Million INR | 32.6% |
| 2019 Q3 | 1.1 Billion INR | 772.09% |
| 2019 Q2 | 126.5 Million INR | 64.71% |
| 2019 FY | - INR | 743.85% |
| 2019 Q4 | -951 Million INR | -186.2% |
| 2019 Q1 | 76.8 Million INR | -86.07% |
| 2018 Q1 | 118.8 Million INR | 181.93% |
| 2018 FY | - INR | -157.89% |
| 2018 Q4 | 551.2 Million INR | 449.75% |
| 2018 Q3 | -157.6 Million INR | -121.44% |
| 2018 Q2 | 735.1 Million INR | 518.77% |
| 2017 Q1 | -230.5 Million INR | 78.65% |
| 2017 FY | - INR | -53.98% |
| 2017 Q4 | -145 Million INR | -117.31% |
| 2017 Q3 | 837.5 Million INR | 10.4% |
| 2017 Q2 | 758.6 Million INR | 429.11% |
| 2016 Q4 | -1.07 Billion INR | -562.0% |
| 2016 FY | - INR | -85.51% |
| 2016 Q2 | 1.19 Billion INR | 29.46% |
| 2016 Q1 | 922.4 Million INR | 11.12% |
| 2016 Q3 | 233.7 Million INR | -80.43% |
| 2015 Q3 | 1.15 Billion INR | -33.9% |
| 2015 FY | - INR | -26.3% |
| 2015 Q1 | 1.86 Billion INR | 130.76% |
| 2015 Q2 | 1.74 Billion INR | -6.42% |
| 2015 Q4 | 830.1 Million INR | -28.19% |
| 2014 Q1 | 765.5 Million INR | -46.43% |
| 2014 FY | - INR | -29.84% |
| 2014 Q4 | 809.8 Million INR | -82.28% |
| 2014 Q3 | 4.57 Billion INR | 242.45% |
| 2014 Q2 | 1.33 Billion INR | 74.37% |
| 2013 FY | - INR | -49.06% |
| 2013 Q4 | 1.42 Billion INR | -56.31% |
| 2013 Q1 | 4.06 Billion INR | -19.11% |
| 2013 Q3 | 3.27 Billion INR | 74.15% |
| 2013 Q2 | 1.87 Billion INR | -53.76% |
| 2012 Q4 | 5.02 Billion INR | -6.71% |
| 2012 Q1 | 4.73 Billion INR | -15.47% |
| 2012 FY | - INR | 51.15% |
| 2012 Q2 | 5.7 Billion INR | 20.66% |
| 2012 Q3 | 5.38 Billion INR | -5.71% |
| 2011 Q4 | 5.59 Billion INR | 64.91% |
| 2011 FY | - INR | 48.23% |
| 2011 Q3 | 3.39 Billion INR | 0.0% |
| 2010 FY | - INR | 9.17% |
| 2009 FY | - INR | 1.9% |
| 2008 FY | - INR | 21.33% |
| 2007 FY | - INR | 64.18% |
| 2006 FY | - INR | 15.82% |
| 2005 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 88.77% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 98.252% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 84.263% |
| Granules India Limited | 8.6 Billion INR | 87.447% |
| Indoco Remedies Limited | 2.64 Billion INR | 59.2% |
| Achyut Healthcare Limited | 524 Thousand INR | -206006.87% |
| Ajanta Pharma Limited | 12.56 Billion INR | 91.405% |
| Alkem Laboratories Limited | 24.19 Billion INR | 95.536% |
| Alpa Laboratories Limited | 86.12 Million INR | -1153.962% |
| Brooks Laboratories Limited | 41.72 Million INR | -2488.19% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 54.175% |
| Bajaj HealthCare Limited | 444.51 Million INR | -142.961% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 26.979% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 98.777% |
| Eris Lifesciences Limited | 6.98 Billion INR | 84.542% |
| FDC Limited | 4.4 Billion INR | 75.464% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 90.479% |
| Gufic Biosciences Limited | 1.48 Billion INR | 27.051% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 84.26% |
| Ipca Laboratories Limited | 13.29 Billion INR | 91.879% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -233.89% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 1405.499% |
| Lasa Supergenerics Limited | -65.08 Million INR | 1759.496% |
| Laurus Labs Limited | 8 Billion INR | 86.51% |
| Lupin Limited | 36.96 Billion INR | 97.079% |
| Mankind Pharma Limited | 28.09 Billion INR | 96.156% |
| Medicamen Biotech Limited | 245.66 Million INR | -339.632% |
| Medico Remedies Limited | 150.37 Million INR | -618.19% |
| Megasoft Limited | 284.73 Million INR | -279.305% |
| NATCO Pharma Limited | 18.79 Billion INR | 94.254% |
| Piramal Pharma Limited | 13.05 Billion INR | 91.728% |
| RPG Life Sciences Limited | 1.28 Billion INR | 15.724% |
| Sigachi Industries Limited | 883.39 Million INR | -22.255% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.219% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 76.909% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -151.002% |
| Unichem Laboratories Limited | 742.35 Million INR | -45.483% |
| Wanbury Limited | 985.49 Million INR | -9.59% |
| Windlas Biotech Limited | 781.72 Million INR | -38.157% |
| ZIM Laboratories Limited | 462.09 Million INR | -133.717% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 98.079% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 128.945% |
| Divi's Laboratories Limited | 25.43 Billion INR | 95.753% |
| Hester Biosciences Limited | 539.47 Million INR | -100.196% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 64.172% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -58.233% |
| Bal Pharma Limited | 345.59 Million INR | -212.507% |
| Strides Pharma Science Limited | 3.76 Billion INR | 71.312% |
| Venus Remedies Limited | 711.8 Million INR | -51.728% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 72.374% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 30.937% |
| Shilpa Medicare Limited | 2.58 Billion INR | 58.269% |
| Aarti Drugs Limited | 3.24 Billion INR | 66.755% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 58.567% |
| Suven Life Sciences Limited | -992.78 Million INR | 208.785% |
| Ind-Swift Limited | 1.06 Billion INR | -1.402% |
| Valiant Laboratories Limited | 12.73 Million INR | -8377.903% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 88.43% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 138.272% |
| Themis Medicare Limited | 562.6 Million INR | -91.963% |
| Hikal Limited | 2.69 Billion INR | 59.885% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 96.915% |
| Sequent Scientific Limited | 549.8 Million INR | -96.435% |
| Novartis India Limited | 1.26 Billion INR | 14.914% |
| Jubilant Pharmova Limited | 8 Billion INR | 86.51% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -8168.259% |
| Neuland Laboratories Limited | 4.74 Billion INR | 77.254% |
| Morepen Laboratories Limited | 1.72 Billion INR | 37.426% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -275.75% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -517.333% |